The 340B Drug Pricing Program continues to prove itself as a vital source of billions of dollars of funding for much needed patient care. Yet, aspects of the program today are facing significant challenges that threaten the very foundation of the program and our safety-net providers. To sort out these legal, policy, and financial complexities, we’re joined by the definitive 340B Program insider, Ted Slafsky.
Ken Perez, Vice President, Healthcare Policy and Government Affairs, Omnicellll
- Ted Slafsky, Publisher and Chief Executive Officer of 340B Report; Founder and Principal of Wexford Solutions